BR112016027580A2 - Formulação de ceritinib - Google Patents

Formulação de ceritinib

Info

Publication number: BR112016027580A2
Authority: BR; Brazil
Prior art keywords: ceritinib; formulation; ceritinib formulation
Prior art date: 2014-05-29

Application number

BR112016027580A

Other languages

English (en)

Other versions

BR112016027580A8 (pt

Inventor

Breulles Sebastien

Ensslin Simon

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-29

Filing date

2015-05-27

Publication date

2017-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016027580(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-05-27 Application filed by Novartis Ag filed Critical Novartis Ag

2017-08-15 Publication of BR112016027580A2 publication Critical patent/BR112016027580A2/pt

2021-06-29 Publication of BR112016027580A8 publication Critical patent/BR112016027580A8/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

BR112016027580A 2014-05-29 2015-05-27 composição farmacêutica compreendendo ceritinib, processo para preparação de um comprimido que compreende o mesmo, e uso de grânulos consistindo de ceritinib e um ligante BR112016027580A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462004359P	2014-05-29	2014-05-29
PCT/IB2015/053966 WO2015181739A1 (en)	2014-05-29	2015-05-27	Ceritinib formulation

Publications (2)

Publication Number	Publication Date
BR112016027580A2 true BR112016027580A2 (pt)	2017-08-15
BR112016027580A8 BR112016027580A8 (pt)	2021-06-29

Family

ID=53298568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112016027580A BR112016027580A8 (pt)	2014-05-29	2015-05-27	composição farmacêutica compreendendo ceritinib, processo para preparação de um comprimido que compreende o mesmo, e uso de grânulos consistindo de ceritinib e um ligante

Country Status (27)

Country	Link
US (4)	US20170112834A1 (pt)
EP (1)	EP3148513B1 (pt)
JP (3)	JP6679578B2 (pt)
KR (1)	KR20170008239A (pt)
CN (1)	CN106456640B (pt)
AR (1)	AR100625A1 (pt)
AU (3)	AU2015265470A1 (pt)
BR (1)	BR112016027580A8 (pt)
CA (1)	CA2948291A1 (pt)
CL (1)	CL2016003047A1 (pt)
DK (1)	DK3148513T3 (pt)
EA (1)	EA036922B1 (pt)
EC (1)	ECSP16096826A (pt)
ES (1)	ES2792574T3 (pt)
HU (1)	HUE048950T2 (pt)
IL (1)	IL248835B (pt)
MX (1)	MX2016015736A (pt)
PE (1)	PE20170313A1 (pt)
PH (1)	PH12016502272A1 (pt)
PL (1)	PL3148513T3 (pt)
PT (1)	PT3148513T (pt)
SG (1)	SG11201609208UA (pt)
SI (1)	SI3148513T1 (pt)
TN (1)	TN2016000484A1 (pt)
TW (1)	TWI721946B (pt)
UY (1)	UY36140A (pt)
WO (1)	WO2015181739A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106176752B (zh) *	2015-05-07	2020-06-23	石药集团中奇制药技术（石家庄）有限公司	色瑞替尼药物组合物
CN109381440A (zh) *	2018-11-15	2019-02-26	威海贯标信息科技有限公司	一种艾乐替尼组合物
CN113244236B (zh) *	2021-06-01	2023-02-03	上海市第一人民医院	色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3632778A (en) *	1970-06-10	1972-01-04	Hoffmann La Roche	Tablets containing l-dopa
KR101364277B1 (ko) *	2006-12-08	2014-02-21	아이알엠 엘엘씨	단백질 키나제 억제제로서의 화합물
PL2091918T3 (pl) *	2006-12-08	2015-02-27	Novartis Ag	Związki i kompozycje jako inhibitory kinazy białkowej
EP2090297A1 (en) *	2008-02-13	2009-08-19	Boehringer Ingelheim International GmbH	Formulations of flibanserin
CN105769792A (zh)	2010-05-11	2016-07-20	田边三菱制药株式会社	含1-(β-D-吡喃葡糖基)-3-(苯基噻吩基甲基)苯化合物的片剂

2015
- 2015-05-27 SG SG11201609208UA patent/SG11201609208UA/en unknown
- 2015-05-27 US US15/313,367 patent/US20170112834A1/en not_active Abandoned
- 2015-05-27 EP EP15727470.5A patent/EP3148513B1/en active Active
- 2015-05-27 EA EA201692310A patent/EA036922B1/ru not_active IP Right Cessation
- 2015-05-27 PE PE2016002399A patent/PE20170313A1/es not_active Application Discontinuation
- 2015-05-27 TW TW104117053A patent/TWI721946B/zh not_active IP Right Cessation
- 2015-05-27 CA CA2948291A patent/CA2948291A1/en not_active Abandoned
- 2015-05-27 TN TN2016000484A patent/TN2016000484A1/en unknown
- 2015-05-27 AU AU2015265470A patent/AU2015265470A1/en not_active Abandoned
- 2015-05-27 DK DK15727470.5T patent/DK3148513T3/da active
- 2015-05-27 KR KR1020167032886A patent/KR20170008239A/ko not_active Application Discontinuation
- 2015-05-27 UY UY0001036140A patent/UY36140A/es not_active Application Discontinuation
- 2015-05-27 SI SI201531221T patent/SI3148513T1/sl unknown
- 2015-05-27 CN CN201580028582.7A patent/CN106456640B/zh active Active
- 2015-05-27 HU HUE15727470A patent/HUE048950T2/hu unknown
- 2015-05-27 ES ES15727470T patent/ES2792574T3/es active Active
- 2015-05-27 PL PL15727470T patent/PL3148513T3/pl unknown
- 2015-05-27 AR ARP150101661A patent/AR100625A1/es unknown
- 2015-05-27 PT PT157274705T patent/PT3148513T/pt unknown
- 2015-05-27 WO PCT/IB2015/053966 patent/WO2015181739A1/en active Application Filing
- 2015-05-27 MX MX2016015736A patent/MX2016015736A/es active IP Right Grant
- 2015-05-27 BR BR112016027580A patent/BR112016027580A8/pt not_active Application Discontinuation
- 2015-05-27 JP JP2017514990A patent/JP6679578B2/ja active Active
2016
- 2016-11-08 IL IL248835A patent/IL248835B/en active IP Right Grant
- 2016-11-15 PH PH12016502272A patent/PH12016502272A1/en unknown
- 2016-11-28 CL CL2016003047A patent/CL2016003047A1/es unknown
- 2016-12-28 EC ECIEPI201696826A patent/ECSP16096826A/es unknown
2018
- 2018-05-01 AU AU2018203007A patent/AU2018203007B2/en not_active Ceased
- 2018-09-26 US US16/142,263 patent/US20190022095A1/en not_active Abandoned
2019
- 2019-09-16 US US16/571,229 patent/US11000523B2/en active Active
- 2019-09-20 AU AU2019232937A patent/AU2019232937B2/en not_active Ceased
2020
- 2020-03-17 JP JP2020046475A patent/JP7084955B2/ja active Active
2021
- 2021-02-05 US US17/168,265 patent/US20210154194A1/en active Pending
2022
- 2022-03-08 JP JP2022034913A patent/JP2022078236A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CA2948291A1 (en)	2015-12-03
SI3148513T1 (sl)	2020-07-31
CN106456640A (zh)	2017-02-22
CL2016003047A1 (es)	2017-04-07
US20210154194A1 (en)	2021-05-27
PE20170313A1 (es)	2017-04-18
SG11201609208UA (en)	2016-12-29
AU2018203007B2 (en)	2019-07-18
HUE048950T2 (hu)	2020-09-28
EA201692310A1 (ru)	2017-04-28
IL248835A0 (en)	2017-01-31
JP6679578B2 (ja)	2020-04-15
US20190022095A1 (en)	2019-01-24
JP7084955B2 (ja)	2022-06-15
KR20170008239A (ko)	2017-01-23
MX2016015736A (es)	2017-03-16
PH12016502272A1 (en)	2017-02-06
EA036922B1 (ru)	2021-01-15
ECSP16096826A (es)	2018-04-30
AU2015265470A1 (en)	2016-11-24
TN2016000484A1 (en)	2018-04-04
CN106456640B (zh)	2021-05-14
US20170112834A1 (en)	2017-04-27
JP2017520619A (ja)	2017-07-27
ES2792574T3 (es)	2020-11-11
EP3148513A1 (en)	2017-04-05
AU2018203007A1 (en)	2018-05-17
JP2020114834A (ja)	2020-07-30
EP3148513B1 (en)	2020-02-26
US20200009141A1 (en)	2020-01-09
AU2019232937A1 (en)	2019-10-10
TW201613580A (en)	2016-04-16
DK3148513T3 (da)	2020-05-25
AR100625A1 (es)	2016-10-19
BR112016027580A8 (pt)	2021-06-29
WO2015181739A1 (en)	2015-12-03
PT3148513T (pt)	2020-05-27
UY36140A (es)	2016-01-08
IL248835B (en)	2020-05-31
TWI721946B (zh)	2021-03-21
AU2019232937B2 (en)	2020-10-15
JP2022078236A (ja)	2022-05-24
PL3148513T3 (pl)	2020-08-24
US11000523B2 (en)	2021-05-11

Legal Events

Date	Code	Title	Description
2019-10-01	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2021-08-17	B350	Update of information on the portal [chapter 15.35 patent gazette]
2021-09-08	B07G	Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]	Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021
2021-09-21	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-12-28	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements

Publication	Publication Date	Title
DK3134402T3 (da)	2020-07-20	4-amino-imidazoquinolinforbindelser
DK3183051T3 (da)	2020-06-02	Væske-til-luftmembranenergivekslere
DK3211743T3 (da)	2019-12-16	Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da)	2019-12-09	Phytasemutanter
DK3119396T3 (da)	2021-05-31	Muscarinreceptoragonister
DK3006072T3 (da)	2021-10-25	Karadgang
DE112015001664A5 (de)	2016-12-29	Betätigungsaktuator
DK3183340T3 (da)	2019-08-19	Termolabile exonukleaser
DK3154703T3 (da)	2020-11-16	Fuldkappe-snekkecentrifuge
DK3110439T3 (da)	2019-05-13	Pcsk9-vacciner
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
DE102014000623A8 (de)	2016-10-13	Halbhohlnietelement
BR112016027580A2 (pt)	2017-08-15	Formulação de ceritinib
DK3009858T3 (da)	2021-08-09	Skyradar
DE112015001633A5 (de)	2017-02-23	Betätigungsaktuator
DK3447493T3 (da)	2020-08-17	Proteinrettede ortologer
ES1133830Y (es)	2015-02-12	Columbario
DK3193856T3 (da)	2021-09-06	Formulering
DK3091875T3 (da)	2019-10-14	Vipbar taburet
DE112015005055A5 (de)	2017-08-03	Gargerätevorrichtung
DK3191825T3 (da)	2019-05-06	Kreatininbiosensor
ES1136182Y (es)	2015-05-08	Senalizador de peldanos fotoluminiscentes
ES1137381Y (es)	2015-06-02	Trompo
ES1136185Y (es)	2015-09-03	Huevera
DOS2014000273S (es)	2015-04-15	Cubito de caldo (caldos)